These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31283854)

  • 1. Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Kelly MJ; Lawton MA; Baig F; Ruffmann C; Barber TR; Lo C; Klein JC; Ben-Shlomo Y; Hu MT
    Mov Disord; 2019 Aug; 34(8):1174-1183. PubMed ID: 31283854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor complications in an incident Parkinson's disease cohort.
    Scott NW; Macleod AD; Counsell CE
    Eur J Neurol; 2016 Feb; 23(2):304-12. PubMed ID: 26074125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
    Hashim HZ; Norlinah MI; Nafisah WY; Tan HJ; Raymond AA; Tamil AM
    Int J Neurosci; 2014 Mar; 124(3):187-91. PubMed ID: 23952588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore.
    Wu J; Lim EC; Nadkarni NV; Tan EK; Kumar PM
    Sci Rep; 2019 Jun; 9(1):9248. PubMed ID: 31239456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
    Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S
    Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease related dyskinesia in a Tanzanian population.
    Dotchin CL; Gray WK; Dewhurst F; Massawe J; Chaote P; Walker RW
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1109-10. PubMed ID: 26173703
    [No Abstract]   [Full Text] [Related]  

  • 19. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
    Jankovic J
    Mov Disord; 2005; 20 Suppl 11():S11-6. PubMed ID: 15822109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.
    Ahlskog JE; Muenter MD
    Mov Disord; 2001 May; 16(3):448-58. PubMed ID: 11391738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.